Mechanism of action
Metformin activates AMP-activated protein kinase (AMPK) in hepatocytes, which is the central energy sensor of the cell. This leads to multiple downstream effects that lower blood glucose without stimulating insulin secretion.
The primary mechanism is decreased hepatic gluconeogenesis. Metformin suppresses the expression of gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, resulting in reduced hepatic glucose output. This accounts for the majority of its glucose-lowering effect.
Metformin also increases peripheral insulin sensitivity in skeletal muscle and adipose tissue by enhancing glucose uptake via increased GLUT4 translocation to the cell membrane. Additionally, it decreases intestinal glucose absorption and reduces circulating free fatty acids, which improves insulin signaling.
Because metformin does not stimulate insulin release from pancreatic beta cells, it does not cause hypoglycemia when used as monotherapy. This insulin-independent mechanism distinguishes biguanides from sulfonylureas and meglitinides.
- Metformin is first-line therapy for type 2 diabetes; it activates AMPK and decreases hepatic gluconeogenesis.
- Metformin does NOT cause hypoglycemia when used as monotherapy because it does not stimulate insulin secretion.
- Hold metformin before IV contrast studies and restart only after confirming normal renal function 48 hours post-procedure.
- Lactic acidosis is the most serious adverse effect; risk factors include renal/hepatic impairment, hypoxia, sepsis, and alcohol abuse.
- Metformin is contraindicated in eGFR <30 mL/min/1.73 m² and should be dose-adjusted in eGFR 30-45 mL/min/1.73 m².
- Common side effects are GI (nausea, diarrhea, abdominal pain); starting low and titrating slowly improves tolerance.
- Long-term metformin use can cause vitamin B12 deficiency leading to megaloblastic anemia and neuropathy.
- Metformin is associated with modest weight loss and reduced cardiovascular mortality in overweight diabetics (UKPDS trial).
Indications
Type 2 diabetes mellitus: Metformin is the first-line pharmacologic agent recommended by all major guidelines for patients with type 2 diabetes, unless contraindicated. It is used as monotherapy or in combination with other antidiabetic agents including sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, and insulin.
Polycystic ovary syndrome (PCOS): Metformin is used off-label to improve insulin resistance, restore ovulatory cycles, and reduce androgen levels in women with PCOS. It is particularly useful in overweight patients with metabolic syndrome features.
Prediabetes and diabetes prevention: Metformin is used off-label in patients with impaired glucose tolerance or impaired fasting glucose to delay or prevent progression to overt diabetes, especially in high-risk groups such as those with BMI ≥35 kg/m², age <60 years, or gestational diabetes history.
Gestational diabetes: In some guidelines, metformin is considered an alternative to insulin for managing gestational diabetes when lifestyle modifications are insufficient, though insulin remains the standard of care in many settings.
Metformin is also associated with modest weight loss (2-3 kg on average), making it particularly suitable for overweight or obese patients with type 2 diabetes.
Pharmacokinetics
Metformin is administered orally and is not metabolized by the liver. Bioavailability is approximately 50-60% under fasting conditions.
Absorption: Metformin is absorbed primarily in the small intestine. Food decreases the extent and slightly delays the rate of absorption. Extended-release formulations allow once-daily dosing and may reduce gastrointestinal side effects.
Distribution: Metformin does not bind significantly to plasma proteins and distributes into erythrocytes. The volume of distribution is large (approximately 654 L).
Metabolism: Metformin is not metabolized and is excreted unchanged in the urine.
Elimination: Renal excretion via tubular secretion is the primary route of elimination. The plasma elimination half-life is approximately 4-6 hours. Because metformin depends entirely on renal clearance, it accumulates in patients with renal impairment, increasing the risk of lactic acidosis.
Dosing follows the product label and is adjusted based on renal function (eGFR). Metformin is contraindicated or requires dose reduction in patients with moderate to severe chronic kidney disease.
Adverse effects
Gastrointestinal effects
The most common adverse effects are nausea, diarrhea, abdominal discomfort, and metallic taste. These occur in up to 30% of patients and are dose-related. Starting with a low dose and titrating gradually, taking the medication with food, or using extended-release formulations can minimize GI symptoms. Most patients develop tolerance over several weeks.
Lactic acidosis
Lactic acidosis is a rare but potentially fatal complication (incidence <1 per 100,000 patient-years). Metformin inhibits mitochondrial complex I in hepatocytes, leading to increased anaerobic metabolism and lactate production. In patients with impaired lactate clearance (renal or hepatic dysfunction, hypoxia, sepsis, or acute heart failure), lactate can accumulate to dangerous levels.
Symptoms include hyperventilation, abdominal pain, hypothermia, hypotension, and altered mental status. Laboratory findings show elevated lactate (>5 mmol/L), low pH (<7.35), and elevated anion gap. Treatment involves discontinuation of metformin, supportive care, and hemodialysis in severe cases.
Vitamin B12 deficiency
Long-term metformin use (>4 years) is associated with decreased vitamin B12 absorption due to impaired calcium-dependent ileal uptake. This can lead to megaloblastic anemia and peripheral neuropathy. Guidelines recommend periodic monitoring of B12 levels, especially in patients with anemia or neuropathy.
Hypoglycemia
Metformin monotherapy does not cause hypoglycemia because it does not stimulate insulin secretion. However, hypoglycemia can occur when metformin is combined with insulin or insulin secretagogues (sulfonylureas, meglitinides).
Other effects
Metformin may cause a mild reduction in thyroid-stimulating hormone (TSH) in patients on levothyroxine. Weight loss of 2-3 kg is common and often considered beneficial.
Contraindications and warnings
Renal impairment: Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). It should be used with caution and dose adjustment in moderate renal impairment (eGFR 30-45 mL/min/1.73 m²). Renal function should be assessed before initiation and monitored periodically.
Acute or chronic metabolic acidosis: Metformin is contraindicated in any form of metabolic acidosis, including diabetic ketoacidosis.
Conditions predisposing to lactic acidosis: Metformin should be avoided in acute heart failure, severe hepatic impairment, severe hypoxic states (respiratory failure, shock, sepsis), acute myocardial infarction, and excessive alcohol intake (acute or chronic). These conditions impair lactate clearance and increase the risk of lactic acidosis.
Radiologic studies with IV iodinated contrast: Metformin should be discontinued at the time of or before the procedure and withheld for 48 hours after contrast administration. Renal function should be reassessed before restarting metformin. This precaution prevents contrast-induced nephropathy from precipitating metformin accumulation and lactic acidosis.
Surgery: Metformin should be held on the day of surgery if general anesthesia or prolonged fasting is anticipated, due to the risk of perioperative lactic acidosis.
Pregnancy and lactation: Metformin is FDA pregnancy category B. It crosses the placenta but is not associated with major congenital malformations. Insulin remains the preferred agent during pregnancy, though metformin is used in some settings for gestational diabetes and PCOS. Metformin is excreted in breast milk in small amounts; the decision to use during breastfeeding should consider maternal benefit versus infant risk.
Drug interactions
Cationic drugs: Drugs that are eliminated by renal tubular secretion (e.g., cimetidine, amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) may compete with metformin for renal elimination and increase metformin levels. Cimetidine can increase metformin AUC by up to 60%.
Alcohol: Acute or chronic alcohol consumption potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis. Patients should be advised to avoid excessive alcohol intake.
Carbonic anhydrase inhibitors: Topiramate and acetazolamide can cause metabolic acidosis and theoretically increase the risk of lactic acidosis when combined with metformin.
Insulin and insulin secretagogues: Concomitant use with insulin, sulfonylureas, or meglitinides increases the risk of hypoglycemia. Dose adjustments of these agents may be necessary.
Drugs affecting glycemic control: Corticosteroids, thiazide and loop diuretics, phenytoin, nicotinic acid, sympathomimetics, thyroid hormones, and estrogens may cause hyperglycemia and reduce the efficacy of metformin. Beta-blockers may mask symptoms of hypoglycemia.
Contrast media: Iodinated contrast agents increase the risk of acute kidney injury, which can lead to metformin accumulation and lactic acidosis (see Contraindications).
Metformin does not inhibit or induce cytochrome P450 enzymes, so drug interactions via hepatic metabolism are not a concern.
Clinical pearls
- Metformin is the only antidiabetic drug proven to reduce cardiovascular mortality in overweight patients with type 2 diabetes (UKPDS study).
- The "hold metformin before contrast" rule is one of the highest-yield clinical facts for exams and practice. Always assess renal function before restarting.
- Metformin causes weight loss or weight neutrality, unlike sulfonylureas, thiazolidinediones, and insulin, which cause weight gain. This makes it an attractive first-line choice.
- Lactic acidosis has a mortality rate of approximately 50% when it occurs. Prevention through appropriate patient selection and monitoring is essential.
- Gastrointestinal side effects are the most common reason for discontinuation. Extended-release formulations and dose titration improve tolerability.
- Metformin is inexpensive and available as a generic, making it accessible in low-resource settings.
- Patients on metformin who develop unexplained hyperventilation, abdominal pain, or altered mental status should have lactate and renal function checked immediately.
- Vitamin B12 should be monitored annually in patients on long-term metformin, particularly those with anemia, peripheral neuropathy, or a history of gastric surgery.
- Metformin has been studied for anti-aging and cancer prevention properties due to its effects on AMPK and mTOR pathways, though these remain investigational uses.
- In PCOS, metformin improves menstrual regularity and may restore ovulation, but it is less effective than clomiphene citrate for inducing ovulation when fertility is the primary goal.
Metformin Must Be Held: Metabolic acidosis, Metformin toxicity (renal failure), Be cautious with contrast, Held before surgery.
Practice questions
1. A 58-year-old man with type 2 diabetes managed on metformin 1000 mg twice daily presents to the emergency department with confusion, abdominal pain, and rapid breathing. His wife reports he has had diarrhea for 3 days and reduced oral intake. Vital signs: temperature 36.2°C (97.2°F), blood pressure 95/60 mmHg, pulse 110/min, respirations 28/min. Laboratory studies show: serum creatinine 3.2 mg/dL (baseline 1.1 mg/dL), lactate 8.5 mmol/L, pH 7.18, bicarbonate 10 mEq/L. Which of the following is the most likely diagnosis?
2. A 45-year-old woman with newly diagnosed type 2 diabetes (HbA1c 8.2%) and BMI of 34 kg/m² is started on metformin. She returns 2 weeks later reporting nausea, loose stools, and abdominal cramping that have prevented her from continuing the medication. Which of the following strategies is most appropriate to improve tolerability?
3. A 62-year-old man with type 2 diabetes on metformin 1000 mg twice daily is scheduled for a CT scan with IV contrast to evaluate abdominal pain. His serum creatinine is 1.3 mg/dL (eGFR 55 mL/min/1.73 m²). Which of the following is the most appropriate management of his metformin?
Frequently asked questions
How does metformin work?
Metformin works by activating AMP-activated protein kinase (AMPK), which decreases hepatic glucose production through suppression of gluconeogenesis. It also increases insulin sensitivity in peripheral tissues like skeletal muscle and adipose tissue, enhancing glucose uptake. Unlike sulfonylureas or insulin, metformin does not stimulate insulin secretion, so it does not cause hypoglycemia when used alone.
What are the side effects of metformin?
The most common side effects are gastrointestinal: nausea, diarrhea, abdominal discomfort, and metallic taste, occurring in up to 30% of patients. The most serious but rare adverse effect is lactic acidosis, which has a high mortality rate and occurs primarily in patients with renal impairment or other conditions impairing lactate clearance. Long-term use can lead to vitamin B12 deficiency, causing anemia and neuropathy.
Why is metformin held before CT contrast?
Metformin is held before IV iodinated contrast administration because contrast agents can cause acute kidney injury (contrast-induced nephropathy). If renal function deteriorates, metformin accumulates in the body since it is eliminated unchanged by the kidneys. This accumulation significantly increases the risk of lactic acidosis, a life-threatening condition. Metformin should be held at the time of or before contrast and withheld for 48 hours afterward, with renal function reassessed before restarting.
Is metformin safe in pregnancy?
Metformin is FDA pregnancy category B and is not associated with major congenital malformations. It crosses the placenta and is used off-label for gestational diabetes and PCOS in some settings, though insulin remains the preferred agent during pregnancy in most guidelines. The decision to use metformin in pregnancy should weigh maternal glycemic control benefits against the lack of long-term safety data in offspring.
Metformin vs glyburide — what is the difference?
Metformin is a biguanide that decreases hepatic glucose production and does not cause hypoglycemia or weight gain, making it first-line therapy for type 2 diabetes. Glyburide is a sulfonylurea that stimulates pancreatic insulin secretion, which can cause hypoglycemia and weight gain. Metformin is preferred due to better safety profile, cardiovascular benefits, and weight neutrality. Glyburide is reserved for patients who cannot tolerate or have contraindications to metformin.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A10BA02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.